ADVERTISEMENT
Ubiquigent appoints Rishi Shah as Head of Chemistry
Prior to Ubiquigent Rishi was with GlaxoSmithKline (GSK)
Rishi Shah / LinkedIn
Ubiquigent Limited, a UK-based drug discovery and development company has announced the appointment of Dr Rishi Shah as head of Chemistry. Shah will be responsible for the firm’s internal drug discovery and strategic partnerships in the design, discovery, and development of deubiquitinase (DUB) focused partnerships.
Commenting on Rishi’s appointment Jason Mundin, chief executive officer at Ubiquigent said, “With almost a decade of experience in heterobifunctional design and biological assay development, Rishi’s expertise will be critical in the continued development of both internal and partner DUB-focused drug discovery programmes and will strengthen our therapeutic focus on DUB-targeting Chimeras (DUBTACs). ”
“Ubiquigent is at an exciting stage of its growth, with an evolving focus on DUBTAC design and development through the application of its comprehensive DUB-focused drug discovery platform,” said Shah.
“I look forward to working alongside the Ubiquigent team to further advance its pipeline of novel DUB modulators, as well as its strategic partnerships with industry and academia, empowering therapeutic progress across the fields of protein degradation and stabilisation,” he added.
Shah was previously with GlaxoSmithKline (GSK) earlier where he led the development of multiple targeted protein degradation (TPD) programmes across a range of therapeutic areas. He has also held a visiting scientist position at Imperial College London.
During that time, He collaborated with professor Ed Tate to merge recent advances in covalent inhibitor technology with Proteolysis Targeting Chimeras (PROTACs),, and has consulted on multiple TPD programmes, including DUB- and molecular glue-focused projects.
In his new role, Shah will also mentor a PhD student from Imperial College Londonas part of the four-year project between the firm and the college that aims to create a new generation of small molecule activity-based probes (ABPs) that will enable DUB activity in intact cells and organisms to be comprehensively explored and interrogated.
ADVERTISEMENT
ADVERTISEMENT
E Paper
Video
.jpg)
.jpg)
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login